Molecular and clinical effects of selective TYK2 inhibition with deucravacitinib in psoriasis
|Study ID||Alternative Stable ID||Type|
Investigate changes in IL-23/Th17- and type I interferon-pathway biomarkers and gene responses, and measures of selectivity for TYK2 over Janus kinases (JAKs) 1–3, in patients with moderate to severe psoriasis receiving deucravacitinib.
Study Datasets 1 dataset.
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
Transcriptomic profiling of skin biopsies from psoriasis patients following treatment with deucravacitinib